Carmot Therapeutics

CompanyUnited StatesFounded 2008

Carmot Therapeutics develops one asset, in phase 3 (enicepatide in obesity). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and GLP1R; based in the United States, founded in 2008.

1
Asset
Furthest stage: Phase 3; 3
Trials: 0
Signals

Pipeline

1

enicepatide
Activates GLP-1 and GIP receptors to support weight management.
Phase 3, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, obesity, obesity or overweight

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms5
Trials3
Signals6
Similar companies6

Papers

Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity
ADA Scientific Sessions 2025 abstract, 13 Jun 2025